A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
ApexOnco Front Page
Recent articles
The company is to test its KLK2-targeting pasritamig in a late-line setting.
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Chengdu Kanghong's KH815 enters human testing this month.
AACR approaches, along with ASCO abstract titles.
A biliary tract cancer trial hits on response rate, but survival data will be key.
